Rankings
▼
Calendar
TELO FY 2024 Earnings — Telomir Pharmaceuticals, Inc. Common Stock Revenue & Financial Results | Market Cap Arena
TELO
Telomir Pharmaceuticals, Inc. Common Stock
$46M
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$12M
Net Income
-$17M
EPS (Diluted)
$-0.56
Cash Flow
Operating Cash Flow
-$5M
Free Cash Flow
-$5M
Stock-Based Comp.
$7M
Balance Sheet
Total Assets
$1M
Total Liabilities
$680,968
Stockholders' Equity
$643,037
Cash & Equivalents
$1M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$12M
-$4M
-210.6%
Net Income
-$17M
-$13M
-26.5%
← Q4 2023
All Quarters
Q1 2024 →